Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0IL0G
|
|||
Former ID |
DNC010582
|
|||
Drug Name |
N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide
|
|||
Synonyms |
CHEMBL1086781; N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C15H15N3O2
|
|||
Canonical SMILES |
CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=COC=C3
|
|||
InChI |
1S/C15H15N3O2/c1-2-3-14(19)16-15-12-5-4-10(8-13(12)17-18-15)11-6-7-20-9-11/h4-9H,2-3H2,1H3,(H2,16,17,18,19)
|
|||
InChIKey |
ZGQZPFJWHPTRAH-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.